Structure-activity relationships of antitubercular nitroimidazoles. 1. structural features associated with aerobic and anaerobic activities of 4 - And 5-nitroimidazoles

Journal of Medicinal Chemistry

Volumn 52, Issue 5, 2009, Pages 1317-1328

  Kim, Pilho ^a,c   Zhang, Liang ^a,d   Manjunatha, Ujjini H ^a,b   Singh, Ramandeep ^a,e   Patel, Sejal ^b   Jiricek, Jan ^b   Keller, Thomas H ^b   Boshoff, Helena I ^a   Barry III, Clifton E ^a   Dowd, Cynthia S ^a,f  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2 BROMO 4 NITRO 1H IMIDAZOLE 1 YL)BUT 3 EN 2 OL; (TERT BUTYLDIMETHYLSILYLOXY) 3 (2 CHLORO 4 NITRO 1H IMIDAZOL 1 YL)PROPAN 2 OL; 2 (2 METHOXY 4 NITRO 1H IMIDAZOL 1 YL)ETHANOL; 2 (2 METHOXY 6 NITRO 1H IMIDAZOL 1 YL)ETHANOL; 2 BROMO [2 (TERT BUTYLDIMETHYLSILOXY)BUT 3 ENYL] 5 NITRO 1H IMIDAZOLE; 3 (TERT BUTYLDIMETHYLSILYLOXY) 2 (TETRAHYDRO 2H PYRAN 2 YLOXY)PROPYL) 2 CHLORO 5 NITRO 1H IMIDAZOLE; 4 NITROIMIDAZOLE DERIVATIVE; 5 NITROIMIDAZOLE DERIVATIVE; 5,6,7,8 TETRAHYDRO 3 NITROIMIDAZO[1,2 A]PYRIDIN 6 OL; 6 (4 (TRIFLUOROMETHOXY)BENZYLOXY) 5,6 DIHYDRO 2 NITROIMIDAZO[1,2 A]PYRIDINE; 6 (TERT BUTYLDIMETHYLSILYLOXY) 3 NITRO 5,6 DIHYDROIMIDAZO[1,2 A]PYRIDINE; 6 (TERT BUTYLDIMETHYLSILYLOXY) 3 NITRO 5,6,7,8 TETRAHYDROIMIDAZO[1,2 A]PYRIDINE; 6 [4 (TRIFLUOROMETHOXY)BENZYLOXY] 5,6,7,8 TETRAHYDRO 2 NITROIMIDAZO[1,2 A]PYRIDINE; 6 [4 (TRIFLUOROMETHOXY)BENZYLOXY] 6,7 DIHYDRO 3 NITRO 5H IMIDAZO[2,1 B][1,3]OXAZINE; 6,7 DIHYDRO 3 NITRO 5H IMIDAZO[2,1 B][1,3]OXAZIN 6 OL; 6,7 DIHYDRO 3 NITRO 6 (TETRAHYDRO 2H PYRAN 2 YLOXY) 5H IMIDAZO[2,1 B]OXAZINE; 6,7 DIHYDRO 6 METHOXY 2 NITRO 5H IMIDAZO[2,1 B][1,3]OXAZINE; [2 (4 (TRIFLUOROMETHOXY)BENZYLOXY)BUT 3 ENYL] 4 NITRO 2 VINYL 1H IMIDAZOLE; [2 (4 (TRIFLUOROMETHOXY)BENZYLOXY)ETHYL] 2 METHYL 4 NITRO 1H IMIDAZOLE; [2 (4 (TRIFLUOROMETHOXY)BENZYLOXY)ETHYL] 2 METHYL 5 NITRO 1H IMIDAZOLE; [2 (4 (TRIFLUOROMETHOXY)BENZYLOXY]BUT 3 ENYL] 2 BROMO 4 NITRO 1H IMIDAZOLE; [2 (TERT BUTYLDIMETHYLSILYLOXY)ETHYL] 2 METHOXY 5 NITRO 1H IMIDAZOLE; [2 (TERT BUTYLDIMETHYLSILYOXY)ETHYL] 2 CHLORO 4 NITRO 1H IMIDAZOLE; [2 (TERT BUTYLDIMETHYLSILYOXY)ETHYL] 2 CHLORO 5 NITRO 1H IMIDAZOLE; NITROREDUCTASE; OXAZINE DERIVATIVE; OXYGEN; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME SUBSTRATE; LIPOPHILICITY; MUTANT; STRUCTURE ACTIVITY RELATION;

AEROBIOSIS; ANAEROBIOSIS; ANTITUBERCULAR AGENTS; KINETICS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; NITROREDUCTASES; OXAZINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64349089269     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801246z     Document Type: Article

References (31)

1. WHO International Fact Sheet No. 104, 2007. http://www.who.int/ mediacentre/factsheets/fs104/en/index.html.
2. Duncan, K.; Barry, C. E. Prospects for new antitubercular drugs. Curr. Opin. Microbiol. 2004, 7, 460-465.
3. Via, L. E.; Lin, P. L.; Ray, S. M.; Carrillo, J.; Allen, S. S.; Eum, S. Y.; Taylor, K.; Klein, E.; Manjunatha, U.; Gonzales, J.; Lee, E. G.; Park, S. K.; Raleigh, J. A.; Cho, S. N.; McMurray, D. N.; Flynn, J. L.; Barry, C. E., 3rd. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun. 2008, 76, 2333-40.
4. Boshoff, H. I.; Barry, C. E., 3rd. Tuberculosis. Metabolism and respiration in the absence of growth. Nat. Rev. Microbiol. 2005, 3, 70-80.
5. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405, 962-966.
6. Barry, C. E.; Boshoff, H. I. M.; Dowd, C. S. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 2004, 10, 3239-3262.
7. Dick, T.; Lee, B. H.; Murugasu-Oei, B. Oxygen depletion induced dormancy in Mycobacterium smegmatis. FEMS Microbiol. Lett. 1998, 163, 159-164.
8. Wayne, L. G.; Sramek, H. A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1994, 38, 2054-2058.
9. Agrawal, K. C.; Bears, K. B.; Sehgal, R. K.; Brown, J. N.; Rist, P. E.; Rupp, W. D. Potential radiosensitizing agents. Dinitroimidazoles. J. Med. Chem. 1979, 22, 583-586.
10. Ashtekar, D. R.; Costa-Perira, R.; Nagrajan, K.; Vishvanathan, N.; Bhatt, A. D.; Rittel, W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. An - timicrob. Agents Chemother. 1993, 37, 183-186.
11. Nagarajan, K.; Shankar, R. G.; Rajappa, S.; Shenoy, S. J.; Costa - Pereira, R. Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo[2,1 - b]oxazoles with antitubercular activity. Eur. J. Med. Chem. 1989, 24, 631-633.
12. Baker, W. R.; Shaopei, C.; Keeler, E. L. Nitroimidazole Antibacterial Compounds and Methods of Use Thereof. U.S. Patent 5,668,127, 1997.
13. Baker, W. R.; Shaopei, C.; Keeler, E. L. Nitro-[2,1-b]imidazopyran Compounds and Antibacterial Uses Thereof U.S. Patent 6,087,358,2000.
14. Lenaerts, A. J.; Gruppo, V.; Marietta, K. S.; Johnson, C. M.; Driscoll, D. K.; Tompkins, N. M.; Rose, J. D.; Reynolds, R. C.; Orme, I. M. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 2005, 49, 2294-2301.
15. http://www.tballiance.org/home/home.php.
16. Sasaki, H.; Haraguchi, Y.; Itotani, M.; Kuroda, H.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Matsumoto, M.; Komatsu, M.; Tsub - ouchi, H. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem. 2006, 49, 7854-7860.
17. Tangallapally, R. P.; Yendapally, R.; Lee, R. E.; Hevener, K.; Jones, V. C.; Lenaerts, A. J.; McNeil, M. R.; Wang, Y.; Franzblau, S. Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. J. Med. Chem. 2004, 47, 5276-5283.
18. Hurdle, J. G.; Lee, R. B.; Budha, N. R.; Carson, E. I.; Qi, J.; Scherman, M. S.; Cho, S. H.; McNeil, M. R.; Lenaerts, A. J.; Franzblau, S. G.; Meibohm, B.; Lee, R. E. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J. Antimicrob. Chemoth - er. 2008, 62, 1037-1045.
19. Yang, C.-C.; Goldberg, I. H. Synthesis of 1-([18O2]-2-nitro-1 - imidazolyl)-3-methoxy-2-propanol([18O2]-misonidazole). J. Labelled Compd. Radiopharm. 1989, 27, 423-434.
20. Liu, Z.-Z.; Chen, H.-C.; Cao, S. L.; Li, R.-T. Solid-liquid phase-transfer catalytic method for N-alkylation of nitroimidazole. Synth. Commun. 1993, 23, 2611-2615.
21. Massip, S.; Guillon, J.; Bertarelli, D.; Bosc, J. J.; Leger, J. M.; Lacher, S.; Bontemps, C.; Dupont, T.; Muller, C. E.; Jarry, C. Synthesis and preliminary evaluation of new 1-and 3-[1-(2-hydroxy-3-phenoxypro - pyl)]xanthines from 2-amino-2-oxazolines as potential A(1)and A(2A)adenosine receptor antagonists. Bioorg. Med. Chem. 2006, 14, 2697-2719.
22. Liu, Z.; Chen, H.; Cao, S.; Li, R. Solid-liquid phase-transfer catalytic method for N-alkylation of nitroimidazole. Synth. Commun. 1993, 23, 2611-2615.
23. Mani, N. S.; Jablonowski, J. A.; Jones, T. K. A scalable synthesis of a histamine H-3 receptor antagonist. J. Org. Chem. 2004, 69, 8115-8117.
24. Gracias, V.; Gasiecki, A. F.; Djuric, S. W. Synthesis of fused bicyclic imidazoles by sequential van Leusen/ring-closing metathesis reactions. Org. Lett. 2005, 7, 3183-3186.
25. Lang, P.; Gerez, C.; Tritsch, D.; Fontecave, M.; Biellmann, J. F.; Burger, A. Synthesis of 8-vinyladenosine 5′-di - and 5′- triphosphate: evaluation of the diphosphate compound on ribonucleotide reductase. Tetrahedron 2003, 59, 7315-7322.
26. Cossy, J.; BouzBouz, S.; Hoveyda, A. H. Cross-metathesis reaction. Generation of highly functionalized olefins from unsaturated alcohols. J. Organomet. Chem. 2001, 624, 327-332.
27. Jourdant, A.; Gonzalez-Zamora, E.; Zhu, J. Wilkinson's catalyst catalyzed selective hydrogenation of olefin in the presence of an aromatic nitro function: a remarkable solvent effect. J. Org. Chem. 2002, 67, 3163-3164.
28. Hoffer, M.; Toome, V.; Brossi, A. Nitroimidazoles. 2. Synthesis and reactions of iodonitroimidazoles. J. Heterocycl. Chem. 1966, 3, 454-457.
29. Manjunatha, U. H.; Boshoff, H.; Dowd, C. S.; Zhang, L.; Albert, T. J.; Norton, J. E.; Daniels, L.; Dick, T.; Pang, S. S.; Barry, C. E., 3rd. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 431-436.
30. Singh, R.; Manjunatha, U. H.; Boshoff, H.; Ha, Y. H.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E., 3rd. Bicyclic nitroimidazoles act as intracellular NO donors and kill non-replicating Mycobacterium tuberculosis. Science, in press.
31. Wayne, L. G. In Mycobacterium Tuberculosis Protocols; Parish, T., Stoker, N. G., Eds.; Humana Press: Totowa, NJ, 2001; pp 247 - 270. JM801246Z